U.S. Markets closed
  • S&P Futures

    3,806.75
    -10.00 (-0.26%)
     
  • Dow Futures

    31,195.00
    -41.00 (-0.13%)
     
  • Nasdaq Futures

    12,629.75
    -52.00 (-0.41%)
     
  • Russell 2000 Futures

    2,196.00
    -9.80 (-0.44%)
     
  • Crude Oil

    61.20
    -0.08 (-0.13%)
     
  • Gold

    1,711.90
    -3.90 (-0.23%)
     
  • Silver

    26.25
    -0.13 (-0.50%)
     
  • EUR/USD

    1.2060
    -0.0007 (-0.0603%)
     
  • 10-Yr Bond

    1.4700
    +0.0550 (+3.89%)
     
  • Vix

    26.67
    +2.57 (+10.66%)
     
  • GBP/USD

    1.3935
    -0.0017 (-0.1254%)
     
  • USD/JPY

    107.0680
    +0.0660 (+0.0617%)
     
  • BTC-USD

    51,538.57
    +2,852.97 (+5.86%)
     
  • CMC Crypto 200

    1,029.97
    +41.88 (+4.24%)
     
  • FTSE 100

    6,675.47
    +61.72 (+0.93%)
     
  • Nikkei 225

    29,126.12
    -432.98 (-1.46%)
     

Edwards Lifesciences: 2Q Earnings Snapshot

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

IRVINE, Calif. (AP) _ Edwards Lifesciences Corp. (EW) on Thursday reported second-quarter profit of $282.7 million.

On a per-share basis, the Irvine, California-based company said it had net income of $1.32. Earnings, adjusted for non-recurring gains, were $1.24 per share.

The results surpassed Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for earnings of $1.13 per share.

The medical device maker posted revenue of $943.7 million in the period, which missed Street forecasts. Nine analysts surveyed by Zacks expected $964.7 million.

For the current quarter ending in October, Edwards Lifesciences expects its per-share earnings to range from 93 cents to $1.03.

The company said it expects revenue in the range of $900 million to $950 million for the fiscal third quarter.

Edwards Lifesciences expects full-year earnings in the range of $4.60 to $4.75 per share, with revenue ranging from $3.5 billion to $3.9 billion.

Edwards Lifesciences shares have risen 38 percent since the beginning of the year, while the Standard & Poor's 500 index has increased 6 percent. In the final minutes of trading on Thursday, shares hit $155.02, an increase of 34 percent in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EW at https://www.zacks.com/ap/EW